Surgery Treatment Articles & Analysis
-
Encouraging Patients to Follow Up
You wish the best for your patients, and following surgery or treatment, it is imperative to understand how their bodies are reacting. Obviously this concerns following up at intervals. However, patients are often under the impression that following up is unnecessary and expensive if they feel fine. The cardiac monitor experts at Medicomp take a look at the realities of patient follow-ups. ...
-
Easyfairs launches beyond beauty live
Easyfairs, owner of the renowned Aesthetics portfolio encompassing the UK’s leading events and publication in medical aesthetics, as well as the recently launched Beyond Beauty magazine, has today announced the launch of a new consumer-facing event, Beyond Beauty Live. The event will provide a platform for those interested in aesthetic treatments and cosmetic surgery to learn from medically ...
By easyFairs
-
Merck Receives Complete Response Letter From US FDA for Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Merck’s supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, the company’s anti-PD-1 therapy, for the treatment of patients with high-risk early-stage triple-negative ...
-
AtriCure to Participate at the Canaccord 41st Annual Growth Conference
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Canaccord 41st Annual Growth Conference. AtriCure’s management is scheduled to present on Wednesday, August 11, 2021, at 8:00 a.m. Eastern Time. Interested parties may ...
-
Valo Announces First Patient Dosed in the OPL-0401 Phase 2 study of an oral ROCK1/2 inhibitor for the Treatment of Non-Proliferative Diabetic Retinopathy
Valo Health, Inc. (“Valo”), the technology company focused on transforming the drug discovery and development process using human-centric data and artificial intelligence, today announced that dosing has commenced in its Phase 2 study — a multi-center ...
-
Centric Medical Announces New Release of Sterile-Packed Rogue+™ Hammertoe Correction System Implants
Centric Medical, the Foot & Ankle division of Life Spine, Inc., which focuses on developing surgical implants for the treatment of distal extremity pathology announced today the release of the ROGUE+ Hammertoe Correction System. This sterile-packed innovative system adds to the original implant design also available, while providing internal fixation via a dual threaded construct which is ...
-
AtriCure to Participate in Upcoming Investor Conferences
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in upcoming investor conferences. AtriCure is scheduled to present at the Stifel 2021 Virtual Healthcare Conference, on Wednesday, November 17, 2021. Management is scheduled to present at 8:40 ...
-
What is Ultrasound HIFU Beauty Machine
At present, ultrasound HIFU beauty machine is the most advanced anti-aging and firming instrument. It uses ultrasound as energy source, uses HIFU (High-Intensity Focused ULtrasound), high-energy focused ultrasonic technology, and can achieve the effect of skin-lifting surgery through non-invasive treatment. The SMAS (fascial layer) is obtained, so it has become the first choice for high-end ...
-
U.S. Stem Cell Confirms Date for Appeals Court Oral Arguments
U.S. Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based, and novel regenerative medicine solutions, is pleased to announce that oral arguments for the company’s court case USA v. U.S. Stem Cell Clinic, et al has been set for the docket beginning January 11, 2021. Since May 9, 2018, U.S. Stem Cell Inc., as one of the parties named, has been challenged ...
-
Centric Medical Announces First Clinical Cases With Saturn External Fixation System
Centric Medical, the Foot & Ankle division of Life Spine, Inc., which focuses on developing surgical implants for the treatment of distal extremity pathology announced today the first clinical cases of SATURN External Fixation System. This System is comprised of various rings, struts, pins, bolts, and other fixation components intended to be used as a means to stabilize bone segments for ...
-
Palisade Bio (Nasdaq: PALI) To Participate In The Virtual Investor Management And KOL Roundtable Event
- Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that members of management will participate in the Virtual Investor Management and KOL Roundtable Event on Tuesday, May 3, 2022 at 10:00 AM ET. Participating from the Palisade Bio management team will be Tom Hallam, Ph.D., Chief ...
By Palisade Bio
-
Endomedix Joins US Army Medical Research Groups in CRADA for Ocular Projectile Battlefield Trauma Project
Endomedix, Inc. announced today that it has entered into a Cooperative Research and Development Agreement or CRADA with the US. Army Institute of Surgical Research (USAISR) and the U.S. Army Medical Materiel Development Activity (USAMMDA). The CRADA will address a specific topic, “Ocular Projectile Battlefield Trauma Project”, an unsolved emergency medical treatment problem for ...
-
Catalyst OrthoScience Announces Todd Wilson, PhD as Vice President of Medical Education and Training
NAPLES, Fla. - Catalyst OrthoScience, a medical device company focused on the upper extremity orthopedics market, is pleased to announce that Dr. Todd Wilson has joined Catalyst as Vice President of Medical Education and Training effective immediately. “We are excited to have an executive with Todd’s experience join our team at Catalyst OrthoScience,” said Catalyst ...
-
Vilex Acquires DT MedTech and the Hintermann Series System Total Ankle Prostheses
Vilex, LLC, a member of the Squadron Capital family of businesses, announced today that it has successfully completed the acquisition of DT MedTech, LLC, whose product lines include the Hintermann Series System™ Total Ankle Replacement (TAR), developed by prominent surgeon, Professor Beat Hintermann. This exceptional TAR system includes the Hintermann Series H3 (H3) 3-piece, mobile-bearing ...
-
Ezisurg Medical presented at the European Bariatric Endoscopic Surgery Congress
On 23-24th September, 2021, the annual European Bariatric Endoscopic Surgery Trends (BEST) was successfully held in Montpellier, France. The BEST congress adopted a unique mode of online and offline access, bringing global experts and scholars together to discuss the cutting-edge progress in the field of bariatric surgery. Ezisurg Medical was honored to become the platinum partner of BEST, and ...
-
Promaxo Announces Sale of In-Office MRI to Arizona State Urological Institute
Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, announced today the sale of its in-office MRI system to Arizona State Urological Institute (“ASUI”). Promaxo’s single-sided MRI with AI based imaging system, FDA cleared for in-office use, empowers practices and hospitals to accurately and seamlessly guide ...
-
TISSIUM Awarded 2.2M€ from i-Nov Competition to Address Chronic Rhinosinusitis
TISSIUM, a privately-owned life science company developing fullysynthetic, biomorphic programmable polymers, announced today it has been awarded 2.2M€ in financing that will accelerate its development of a drug-eluting tissue adhesive to address the unmet needs of Chronic Rhinosinusitis (CRS) patients. The funding comes from the Investments for the Future program (Programme ...
By TISSIUM
-
New Study Gets to the Root of Fixing Pediatric Flatfeet
GraMedica is pleased to announce that the research team of Dr. Philip J. Bresnahan and Dr. Mario A. Juanto have published a new study this month focused on the misinformation surrounding the treatment of a common deformity known as pediatric flatfeet. Pediatric flatfeet are caused by the partial dislocation of the ankle bone on the heel bone. Historically, many medical professionals have not ...
By GraMedica
-
Palisade Bio (Nasdaq: PALI) To Present New Clinical Data Of LB1148 For Preventing Adhesions In Conjunction With Next Big Thing Session At Society Of American Gastrointestinal And Endoscopic Surgeons 2022 Annual Meeting
Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, was selected to present an ePoster entitled “Pooled-Analysis of Incidence and Severity of Post-Surgical Intraabdominal Adhesions following Bowel Resection Surgery and Treatment with Enteral Protease Inhibitor LB1148” at The Next ...
By Palisade Bio
-
New Publication on TIF 2.0 in Therapeutic Advances in Gastroenterology Provides a Roadmap as Surgeons and Gastroenterologists Partner to Use the Procedure to Achieve Optimal Outcomes for Patients with Gastroesophageal Reflux Disease (GERD)
Continued evolution of EndoGastric Solutions’ EsophyX technology and concomitant use of TIF 2.0 with hiatal hernia repair brings long-term GERD relief to a broader spectrum of patients REDMOND, Wash – June 17, 2020 – EndoGastric Solutions® today announced the publication of a new review article in Therapeutic Advances in Gastroenterology1 that describes the refinement of ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you